What Is Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive form of malignant blood system disease in which the bone marrow produces abnormal myeloid cells. These immature cells (blasts) multiply rapidly, crowding out normal blood cells—red blood cells, platelets, and healthy white blood cells. The disease requires immediate diagnosis and inpatient treatment [7].
Main Symptoms of Blood Cancer
Clinical manifestations of AML develop rapidly due to a deficiency of normal blood cells and body intoxication. Patients and physicians typically encounter the following signs:
- Pronounced general weakness, rapid fatigue, and skin pallor (a consequence of anemia) [8].
- Frequent infectious diseases and fever of unknown origin due to a lack of functional leukocytes [7].
- Tendency to bruise, bleeding gums, and nosebleeds due to low platelet levels [8].
- Bone and joint pain caused by the bone marrow being crowded with tumor cells [8].
The Role of Chemotherapy in AML Treatment
Intensive chemotherapy remains the main method of combating the disease. The treatment process is traditionally divided into two stages:
- Induction therapy: aimed at destroying the maximum number of leukemic cells and achieving remission, in which blood and bone marrow counts return to normal.
- Consolidation therapy (post-remission): performed to solidify the result and destroy remaining microscopic foci of the tumor to prevent relapse [7].
In some cases, for high-risk patients, the possibility of hematopoietic stem cell transplantation is considered after chemotherapy.
Prognosis and Survival Factors
The prognosis for acute myeloid leukemia depends on many factors, including the patient's age, general health status, concomitant pathologies, and the genetic characteristics of the tumor cells [8]. Early detection of the disease and timely initiation of treatment significantly increase the chances of achieving sustained remission and improving the patient's quality of life.
Sources
- [1] Predicting clinical exacerbations using respiratory oscillometry during home telemonitoring of patients taking medium-/high-dose asthma treatment. PubMed
- [2] Appetite and body weight changes after MR-guided laser interstitial thermal therapy of hypothalamic hamartomas in children with drug-resistant epilepsy. PubMed
- [3] Predicting disease progression in multiple sclerosis with clinically accessible information and technology. PubMed
- [4] Early Prognostic Factors in Multiple Sclerosis: Clinical and Therapeutic Implications. PubMed
- [5] Carisbamate treatment of adult and pediatric patients with Lennox-Gastaut syndrome: A phase 1 pharmacokinetic, safety, and tolerability study. PubMed
- [6] Demographic and Clinical Characteristics of Patients Treated With Lecanemab Stratified by Amyloid-Related Imaging Abnormality Status. PubMed
- [7] Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences. PubMed
- [8] Clinical characteristics, laboratory measures, and quality of life as predictors of medication adherence in multiple myeloma. PubMed
Disclaimer: The information provided in this article is for reference purposes only and does not replace an in-person consultation with a qualified oncologist or hematologist.